BioSpace News Archive

HeartBeam, Inc. today announced the appointment of Ken Nelson and Mark Strome to its board of directors, effective as of June 5, 2023.

Enochian BioSciences Inc. (the Company) announces that it remains confident in submitting an Investigational New Drug Application (IND) for its innovative Cancer Platform in early/mid 2024 following review of comments made by the US Food and Drug Administration on the Company’s Pre-IND submission.

Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, announced that Todd R. Nelson, Ph.D., CEO and Founder of Telesis Bio will present today at the 2023 Jefferies Healthcare Conference, Thursday, June 8, 2023, at 10:00 am Eastern time / 7:00 am Pacific Time.

Biora Therapeutics, Inc. (Nasdaq: BIOR) today announced that it will present preclinical data on oral delivery of a GLP-1 receptor agonist with its BioJet systemic oral delivery platform in a short oral discussion at the 59th annual meeting of the European Association for the Study of Diabetes, to be held October 2–6, 2023 in Hamburg, Germany.

Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) (“Dermata” or the “Company”) today announced that positive results from its DMT310 Phase 2b study of its once-weekly topical treatment in patients with moderate-to-severe acne vulgaris was published in the prestigious, peer-reviewed Journal of the American Academy of Dermatology (JAAD).

Avidity Biosciences, Inc. (Nasdaq: RNA) today announced that the company will be presenting two oral presentations and two poster presentations at the 30th Annual FSHD Society International Research Congress, being held June 15-16, 2023, in Milan, Italy.

Brussels, 7th of June 2023 – Newton Biocapital (NBC), a venture capital firm focused on investing and growing early-stage life sciences companies in Europe and Japan targeting chronic health conditions

Founded in 2019 to use technology to help improve patient care and outcomes, CCN Health, a remote patient monitoring (RPM) system provider, quickly began to struggle with customer service issues associated with the Bluetooth® devices it was using.

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic” or the “Company”), a medical imaging device company, announces that effective May 31, 2023, Dr. John McGraw has resigned as Chief Executive Officer